Favorable Immune Reconstitution in Patients Administered Anti-Thymocyte Globulin (ATG) Early in the Course of Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation

胸腺球蛋白 抗胸腺细胞球蛋白 医学 移植 内科学 移植物抗宿主病 胃肠病学 队列 氟达拉滨 全身照射 免疫学 梅尔法兰 造血干细胞移植 阿勒姆图祖马 化疗 环磷酰胺 他克莫司
作者
Viktoriya Zelikson,Natasha Raman,Anatevka Rebiero,Elizabeth Krieger,Catherine Roberts,Gary Simmons,Amir A. Toor
出处
期刊:Blood [Elsevier BV]
卷期号:136 (Supplement 1): 16-17
标识
DOI:10.1182/blood-2020-138581
摘要

Anti-thymocyte globulin (ATG) mitigates graft vs host disease (GVHD) risk in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Due to T cell depletion there remains a concern that ATG administration may be associated with an increased risk of malignancy, relapse, and infection in recipients of reduced intensity conditioning (RIC). It was hypothesized that ATG infusion early in the course of conditioning will promote rapid immune reconstitution because of lower levels at the time of graft infusion and will thus help to improve clinical outcomes in RIC. Rabbit ATG (Thymoglobulin, Sanofi Aventis) was administered from day (d) -9 to -7 to HLA matched-unrelated (MUD; 5 mg/kg in divided doses) and -related (MRD; 3.5 mg/kg) donor transplant recipients conditioned with Fludarabine and Melphalan (ATG -9 cohort; N=36). Immune reconstitution and clinical outcomes were compared with a historical control group of patients who received the same doses of ATG from d-3 to -1 (ATG -3 cohort; N=28). Standard GVHD prophylaxis with calcineurin inhibitor and antimetabolite was administered, with CMV and EBV monitoring. ATG -9 cohort had more, MUD recipients 80% vs. 64%; myeloid malignancy (AML, MDS, MPD) 83% vs. 35%. Age (56 vs. 57), graft type (97 vs. 92% PBSC) and CD34+cell dose infused (4.8 vs 4.7 E6/KG) were similar. Immune reconstitution was uniformly superior in ATG -9 cohort, with significantly higher absolute monocyte counts (AMC) at d30, 60 and 90 (P<0.001), as well as higher donor derived CD3+ (ddCD3+) and CD3+/8+ cell counts at d60 and 90 (P<0.01), and CD3+/4+ cells at d90 (P=<0.05). T cell - monocyte interactions were modelled as 2 dimensional vectors in the immune phase space, (Figure 1) with a consistently higher vector magnitude observed in ATG-9 cohort (P<0.01). Rate of T cell reconstitution was determined by calculating the derivative of ddCD3+ cell count as a function of time (dT/dt) post-transplant (Figure 2) and was generally higher in the ATG-9 cohort, particularly at d60. With a median follow up of 14.9 months in the ATG-9 cohort, and 47.2 months in the ATG -3 cohort, there is a non-significant trend for improved survival (72.2% vs. 46.4% at 2 years) and relapse (19.4% vs. 35.7% at 2 years) in the ATG -9 cohort. TRM and acute GVHD were similar, with a trend towards greater risk for chronic GVHD in the ATG -9 cohort, albeit of a lower severity. Given the relatively low number of patients in each cohort, the effect of immune reconstitution on clinical outcomes was evaluated in the pooled population. Survival was improved in those with AMC and ddCD3+ cell counts >200/µL at d60 (P=0.004 & 0.016 respectively), and in patients with T cell - monocyte vector magnitude > median (577.48/µL) at that time (P= 0.008), as well as in those with a calculated dT/dt > median (1.96 cells/µL/day) at d45 (P=0.047). The latter was also associated with a reduction in relapse rate (P=0.04), as was ddCD8+ cell count >145/µL at d60 (P=0.04). Acute GVHD risk was increased when dT/dt was >median (7.60 cells/µL/day) at d15 (P=0.0095), and correspondingly with T cell - monocyte vector magnitude > median (1033.3/µL) at d30 (P=0.017). In conclusion, this retrospective study demonstrates that equal doses of ATG administered earlier (d -9 to -7 as opposed to d-1 to -3) during conditioning yield more rapid and robust immune reconstitution. Monocyte and ddCD3+ cell recovery kinetics have a favorable impact on survival and relapse risk following HLA matched HCT. Patients at risk for acute GVHD may be identified as early as d15 post HCT by analyzing ddCD3+ cell reconstitution kinetics. Different ATG administration schedules should be studied prospectively with a focus on immune reconstitution kinetics as a determinant of clinical outcomes. Disclosures No relevant conflicts of interest to declare. OffLabel Disclosure: Rabbit anti-thymocyte globulin for GVHD prophylaxis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
戌博完成签到,获得积分10
1秒前
竹子发布了新的文献求助10
2秒前
彭于晏应助cb采纳,获得10
2秒前
葫芦娃完成签到,获得积分10
3秒前
Jasper应助iShine采纳,获得10
3秒前
lelele发布了新的文献求助10
4秒前
4秒前
5秒前
dongdoctor完成签到 ,获得积分10
5秒前
魏莱发布了新的文献求助10
5秒前
Ulrica完成签到,获得积分10
5秒前
CipherSage应助包容追命采纳,获得10
5秒前
owldan完成签到 ,获得积分10
7秒前
一直向前完成签到,获得积分10
7秒前
舒服的映安完成签到 ,获得积分10
7秒前
lmh011115发布了新的文献求助10
8秒前
9秒前
一直向前发布了新的文献求助10
9秒前
End完成签到 ,获得积分10
10秒前
沉静的红酒完成签到,获得积分10
11秒前
yzxzdm完成签到 ,获得积分10
11秒前
Yara.H完成签到 ,获得积分10
11秒前
Meng完成签到,获得积分10
12秒前
14秒前
量子星尘发布了新的文献求助10
16秒前
包容追命发布了新的文献求助10
18秒前
18秒前
梦鱼完成签到,获得积分10
19秒前
小林不熬夜完成签到,获得积分10
19秒前
玛卡巴卡完成签到,获得积分10
20秒前
希尔伯特发布了新的文献求助10
22秒前
Jasper应助dailyyang采纳,获得10
22秒前
冬凌草完成签到 ,获得积分10
22秒前
阿若完成签到,获得积分10
22秒前
英姑应助单纯冰棍采纳,获得10
22秒前
高高从霜完成签到 ,获得积分10
23秒前
lmh011115完成签到,获得积分10
23秒前
包容追命完成签到,获得积分20
24秒前
zhenya完成签到,获得积分10
25秒前
xiang929完成签到 ,获得积分10
27秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038446
求助须知:如何正确求助?哪些是违规求助? 3576149
关于积分的说明 11374627
捐赠科研通 3305875
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892680
科研通“疑难数据库(出版商)”最低求助积分说明 815048